Accelerating precision medicine of cancer with SomaScan® proteomics

Accelerating precision medicine of cancer
with SomaScan proteomics

Proteomics has emerged as the next frontier in precision medicine, and several innovative proteomics platforms have been developed to drive biomarker discovery. We [at Beth Israel Deaconess Medical Center] are using the currently most comprehensive proteomics technology — the SomaScan Platform, which measures 7,000 proteins — to discover and independently validate diagnostic, predictive, and prognostic biomarkers for various cancers.

Efforts are especially focused on non-invasive biomarkers in serum, plasma, urine, and exosomes for a broad range of clinically highly relevant and challenging indications. Protein biomarker efforts for early detection of liver cancer and for predicting response to immunotherapy in metastatic melanoma will also be presented.

Learn about:

  • Plasma protein biomarkers for predicting response to immunotherapy in metastatic melanoma
  • Serum protein biomarkers for differential diagnosis of oral squamous cell carcinoma
  • Plasma protein biomarkers for pancreatic cancer
  • Exosome protein biomarkers for pancreatic cancer
  • Urine protein biomarkers for pancreatic cancer and triple negative breast cancer
  • Pre-diagnostic plasma protein biomarkers for early detection of hepatocellular cancer

Towia Libermann, PhD

Towia Libermann, PhD

Towia Libermann, PhD, is Associate Professor of Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center. He is also the Director of the Beth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center and of the Dana Farber/Harvard Cancer Center Cancer Proteomics Core.

Accelerating precision medicine of cancer with SomaScan proteomics

A presentation by Towia Libermann, PhD

More resources for cancer research

Maximize target selection and validation with high-plex protein profiling

Learn more

Efficient development of prognostic tests for detecting cancer risk using proteomic technology

See poster

The plasma proteome as a cardiovascular disease risk assessment tool in cancer survivors

See poster

Share with colleagues

More webinars

WebinarImproving clinical development productivity with high-plex proteomics

While the vast majority of approved pharmaceuticals target proteins, knowledge of the full complement of proteins that are acted on by drugs, or are potentially druggable, remains incomplete. Assessment of the human proteome is thus increasingly recognized as a priority for successful and cost-effective drug development and clinical research.

Learn more

WebinarMillions for Proteomics Research in the Peer Reviewed Medical Research Program

How SomaLogic Technologies can give your research programs an edge

Learn more

WebinarA proteomics signature of NASH

There is a high unmet need for non-invasive tests that can robustly and reliably assess NAFLD for diagnosis, prognosis, and monitoring purposes. Large-scale profiling of serum/plasma proteins (proteomics) increasingly demonstrates utility to identify changes that accurately reflect and predict disease states and outcomes, including the fibrosis component of NASH that is driven by disease activity and remains the most robust histological marker of prognosis.

Learn more